Two reports have shown a
Botulinum toxin (BTX) is a well established, effective treatment for torticollis,1-7 blepharospasm,8 9 and laryngeal dystonia. 101I New indications for BTX treatment also being evaluated include focal hand dystonias,'2-"7 tremor,'8 and spasticity. '9 20 Of the seven immunologically distinct types of botulinum neurotoxins, labelled A to G,21 the only type in routine clinical use at present is botulinum toxin type A (BTX-A).
Although most patients with torticollis benefit from BTX, about 10% never respond to treatment (primary non-responders)22-24 and up to 10% of patients may become resistant to treatment after initially responding (secondary non-responders). 25 Technical factors such as incorrect storage or reconstitution of the toxin may be responsible for isolated secondary treatment failures. Explanations for sustained late failure of response include underdosing, injection of inappropriate muscles, a worsening or change in the pattern of dystonia, possibly with involvement of deep, inaccessible muscles, development of contractures, altered perception of response, and the development of immunity.2325 Immunity is particularly suspected when injected muscles fail to become atrophic; antibodies to botulinum toxin are often present in such patients.2526 Risk factors for the development of antibodies seem to be higher frequency of injections, the use of "booster" injections and higher doses of BTX per treatment,25 and possibly cumulative dose and small body size.2327 Antibodies have been detected after treatment with each type of BTX-A in use (Botox and Dysport). 23-26 28-30 Secondary non-responders who have developed immunity to BTX-A should be theoretically ideal candidates for treatment with types of BTX that are immunologically distinct from type A. It has already been established that their dystonia responds to weakening of the affected muscles with BTX but assumes that the resistance (immunity) is specific to BTX-A and that this is the only reason for failure of treatment. Two groups have reported successful treatment of patients who have developed antibodies and clinical resistance to the Botox form of BTX-A using a Japanese preparation of botulinum toxin type F (BTX-F).263132
We report the first results of open labelled treatment of patients with torticollis clinically resistant to Dysport BTX-A with another preparation of BTX-F.
Patients and methods
Six patients clinically resistant to BTX-A were selected from a large torticollis clinic. Five had initially obtained a definite benefit (secondary non-responders) and one had never responded to treatment (primary non-responder). All had ultimately failed to develop atrophy in injected muscles. The study had the approval of the hospital ethics committee and all patients gave informed consent. The BTX-A (Dysport) and BTX-F used in this study were produced and supplied by Speywood Pharmaceuticals. INJECTION 
PROTOCOL
On entry into the study, the patients received one further treatment with BTX-A and were reviewed two weeks later. This was to confirm that they were still clinically resistant to BTX-A because of the sometimes long interval since the cessation of regular BTX-A injections due to treatment failure. The target muscles in the neck and the doses given to each were chosen and injected (without EMG guidance) by a physician (AJL) with considerable experience in the treatment of this condition. The doses of BTX-A (400-500 mouse units; MU) were based on this experience. Based on the LD5, data for BTX-F, using the same method as that used to evaluate potency of their BTX-A product, the suppliers suggested an initial total dose of 260 MU of BTX-F, to be divided among the affected muscles. This dose was deliberately low for safety reasons as this preparation of BTX-F had not been tried on humans before. Provided that there were no adverse events with the lower dose, a subsequent total dose of 520 MU was suggested, this being comparable with the average dose of BTX-A used, again to be divided among the affected muscles. Vials of BTX-A contained 500 MU each and were diluted with 2-5 ml of sterile normal saline to a concentration of 200 MU/ml. Vials of BTX-F contained 260 MU each and were diluted with 2-5 ml of normal saline to a concentration of 100 MU/ml. The commonest muscles injected were the sternomastoid and splenius and less often the semispinalis and trapezius.
At least six weeks after the BTX-A injection, ensuring that there was no clinical effect of this injection, the patients received an injection of a total dose of 220 MU of BTX-F and were reviewed after two and six weeks. At the six week review, a second injection of a total of 520 MU BTX-F was given if there was no residual response to the first injection of BTX-F, and the patients were reviewed again two and six weeks later. Immediately after the injection of 220 MU of BTX-F to the neck, the electrophysiological tests were performed (as before), followed by an injection of 40 MU of BTX-F (the remainder of the vial of 260 MU) into the right extensor digitorum brevis muscle, the side opposite that which received BTX-A. Electrophysiological testing was repeated at two and four weeks as before.
SEROLOGICAL TESTING
Blood was taken on entry into the study, on the same day and just before receiving the BTX-A neck injection, to test for antibodies to BTX-A. The details of the mouse protection assay are similar to those previously reported.29 STATISTICAL 
ANALYSIS
The Tsui scores, video ratings, and the electrophysiological data before and after the injections were compared with the Wilcoxon rank sum test. P values < 0 05 were considered significant. Table 1 gives the clinical details of the patients. There were five women and one man, ranging in age from 27 to 63 (mean 47'8) years. One patient was a primary nonresponder and the remaining five were secondary non-responders. The patients were declared clinically resistant to BTX-A injections after seven to 18 treatments (mean 13, median given over a period of 18 to 83 months (mean 43-8, median 43-5 months). The total dose of BTX-A received by the patients, before treatment was abandoned due to resistance, ranged from 4000 to 12 300 MU (mean 8383 MU, median 8850 MU).
Results

RESPONSE TO BTX INJECTIONS
After injection of BTX-A, there was no significant change in the Tsui scores of the group at Similarly for the results after 220 MU BTX-F.
The duration of response in the three patients who reported subjective improvement after the lower dose of BTX-F (220 MU) ranged from two to four weeks. The mean duration of response after 520 MU BTX-F was five (range 4-6) weeks and all responders stated that the duration of benefit was much shorter than that previously experienced with BTX-A (usually 10 to 12 weeks). Two of the three patients responding to the lower dose reported a benefit of increased magnitude and longer duration after the higher dose; the third patient reported considerable improvement after both doses but a longer duration of response with the higher dose. The onset of benefit began within two weeks, except for one patient in whom the response was delayed with the low dose of BTX-F to just beyond two weeks; with the higher dose, the onset was within two weeks.
Side effects were reported in only two patients and only after the higher dose of BTX-F. One (patient 3) experienced a dry mouth and mild dysphagia for a few days; this dose had produced a moderate subjective improvement. The other patient (patient 2) reported a dry mouth for a few days, but no dysphagia, accompanied by a pronounced benefit. All patients received injections of BTX-F into the sternomastoid and developed some degree of atrophy subsequently, although this was substantial in only two. Another group have also reported their experience with BTX-F in 10 patients, seven of whom had torticollis. 32 All patients were clinically resistant to BTX-A and had antibodies detected with a bioassay; all improved after treatment with BTX-F for a period of six to 10 weeks. Side effects were reported to be similar in frequency and severity to those with BTX-A treatment.
These studies of BTX-F, including our own, have been uncontrolled and have involved few patients. Despite this, it seems that most secondary BTX-A non-responders will benefit from BTX-F. Biological sensitivity *Wasting: -= no wasting, +++ = severe wasting of EDB; t no significant change from baseline; t significant change from baseline (P < 0 05, Wilcoxon rank sum test). Sheean 
response, even if the patient was previously responsive to BTX-A. It is well known from biologically sensitive primary and secondary non-responders that factors other than immunity must be involved in a lack of clinical response. These include a change in the pattern of affected muscles, possibly involvement of deep, inaccessible muscles, insufficient doses, injection of inappropriate muscles, failure to place the toxin accurately within the muscle, or the development of contractures.2'24 Such factors may have contributed to the late failure of BTX-A, in addition to immunity, or may have intervened in the meantime to render the patients unresponsive to BTX-F. Although the numbers are small, primary nonresponders seem less likely to respond to BTX-F (one of four patients in this study and those from Greene et a126) suggesting that factors independent of the type of toxin used are chiefly responsible for the lack of response.
Our primary non-responder (patient 1) was resistant both biologically and clinically to BTX-A. She had been managed aggressively with escalating doses and injections of different muscles, including treatment sessions involving injections of up to four muscles at a time with a total dose of 1100 MU of BTX-A. Despite biological resistance, antibodies to BTX-A were not detectable. The frequency of antibodies detected by bioassay in cases of clinical resistance to BTX-A ranges from 11 to 60%.232527 This may be an underestimate as not all patients with clinical resistance are tested. Furthermore, it is not always clear from these reports whether the patients are also biologically resistant (lack of atrophy). Thus factors other than this may be responsible for the clinical resistance and may partly explain the low incidence of antibodies in cases of secondary resistance. On the other hand, only three out of eight patients (38%) who were both clinically and biologically resistant had antibodies in one study. 25 Therefore, even when biologically resistant, antibodies may not be detectable. Such seronegative cases, including our primary non-responder, may reflect the technical difficulty and insensitivity of the mouse bioassay. Alternatively, some other nonhumoral factor may underlie the resistance in antibody negative patients. Animals inoculated with botulinum toxoid may be protected from its neurotoxic effects despite the absence of antibodies with the mouse bioassay."
The frequency of antibodies on mouse bioassay in patients continuing to respond to BTX-A is also difficult to estimate given that such testing is usually only performed when there is a diminished clinical response. Whereas there are occasional reports of seropositivity among continuing responders,2427 screens of such patients generally yield negative results.23 24 A mean duration of response to BTX-F of five weeks in this study is similar to that reported by Greene et al 26 and is much shorter than our experience with BTX-A, which is around 12 weeks.7 The mean duration of benefit in the four patients treated with BTX-F by Ludlow et al"l was longer at 7-5 weeks (range 6-10 weeks in their later expanded report),'2 although in three patients the response was shorter than that previously experienced with BTX-A. The reason for this difference in the duration of benefit using BTX-F from the same source (Japanese) is not clear but may involve the different injection techniques and the different assay estimates of toxin potency obtained by each institution. It had been suggested that the duration of response may be different in facial or laryngeal muscles,26 but a study of blepharospasm seems to confirm a shorter duration of action for BTX-F, regardless of muscle size. '4 We have the advantage that the potencies of BTX-F and BTX-A used in this study were determined by the same method. According to the manufacturer's current information, the specific activities (units of biological activity per unit amount of toxin) of the two types of BTX are virtually identical. Thus equal amounts of each type of toxin should have the same biological activity, or at least the same lethal activity in mice. This may not mean that they have equal muscle weakening effects. Animal studies suggest that BTX-F produces less potent neuromuscular junction blockade and has a shorter duration of action than BTX-A.'5 The initial dose of BTX-F used in the present study was low for safety reasons whereas the higher dose of 520 MU is similar (in MU) to the doses of BTX-A used in the routine clinic. It is still possible, however, that the short duration of response we noted was due to relative underdosing. The three patients responding to the lower dose (220 MU) of BTX-F obtained benefit from the higher dose (520 MU) of BTX-F which was of longer duration, or greater magnitude,or both, suggesting that the degree and duration of response may be dose related, similar to BTX-A. Furthermore, atrophy of the stemomastoid was often not prominent and only one patient experienced side effects due to regional weakness (mild dysphagia) with the higher dose of BTX-F; dysphagia was reported after 44% of treatments with BTX-A in a review of the results from this institution.24 Therefore, even higher doses of BTX-F may have provided a greater response of longer duration. Although the dilutions of the two types of toxin used (A and F) were different, this could only be expected to affect the degree of benefit and not the duration. All of our patients developed near total atrophy of the extensor digitorum brevis muscle after injection of 40 MU of BTX-F but we have no experience of injections of this muscle with BTX-A for comparison. Although we did not follow the time course of the physiological responses of the BTX-F injections into the extensor digitorum brevis muscle, it is the duration of clinical response which is more important. Cross reactivity between the anti-BTX-A antibodies and BTX-F has also been suggested to explain the shorter duration of BTX-F,2632 even though this does not occur experimentally. 36 If lower potency and a shorter duration of clinical action of BTX-F is confirmed, this will necessitate the use of higher doses more often, variables which have been identified as risk factors for antibody development to BTX-A. 25 This could limit the value of BTX-F in long term treatment and it may not prove to be a practical solution for patients with torticollis clinically resistant to BTX-A. A preliminary report37 on the use of BTX-B as primary treatment in torticollis looks promising but as yet there are no data concerning its use in patients clinically resistant to BTX-A. Treatment with BTX-F might also be of value in the rare situation where treatment with BTX-A has become contraindicated because of complications which are possibly immune mediated.40A2
Greene et al 26 suggested several situations in which use could be made of the shorter duration of action of BTX-F. Another may be treatment of writer's cramp and other task specific dystonias in which a stepwise approach with very fine adjustments of BTX doses and muscles injected is sometimes needed and where excessive weakness is poorly tolerated and may last for three months or more. It may be possible to optimise the treatment (muscles injected and degree of weakness) with BTX-F first and then continue with BTX-A.
In summary, BT`X-F is a potentially useful alternative for those who have failed to respond to BTX-A, particularly secondary non-responders. As with BTX-A, biological sensitivity to BTX-F does not guarantee a clinical response and other causes of clinical resistance should be considered. Although there are still some questions about the dose-response relation, the duration of benefit seems to be shorter than with BTX-A.
The need for higher doses more frequently could limit the clinical value of BTX-F and possibly make it more immunogenic. Further dose ranging and long term studies are needed.
